CJC-1295 with DAC
Also known as: CJC-1295 DAC, Drug Affinity Complex CJC-1295
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Overview
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
Key benefits
- Convenient weekly dosing
- Sustained GH/IGF-1 elevation
- 6-8 day half-life
- Significant body composition changes
Mechanism of action
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.
Molecular data
- Type
- GHRH analog with DAC
- Half-life
- 6-8 days
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys
Indications
What the research community uses this compound for, with self-reported effectiveness.
Growth Hormone
Sustained GH Elevation
Most effectiveContinuous growth hormone release for 6-8 days per injection.
IGF-1 Optimization
Most effectiveSignificantly elevates IGF-1 levels for extended periods.
Convenience Protocol
EffectiveWeekly dosing ideal for simple administration.
Body Composition
Fat Loss Enhancement
EffectiveContinuous GH elevation promotes lipolysis and fat metabolism.
Lean Mass Gains
EffectiveSustained anabolic environment supports muscle protein synthesis.
Anti-Aging
Recovery Enhancement
ModerateAccelerated healing and recovery from exercise or injury.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Subcutaneous injection is the preferred route for DAC variant.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Conservative Anti-Aging | 1mg | Once weekly | SubQ |
| Standard Protocol | 2mg | Once weekly | SubQ |
| Split Dosing | 1mg | Twice weekly (Mon/Thu) | SubQ |
| Loading Protocol | 2mg first week, then 1mg | Weekly | SubQ |
Preparation
You will need
- CJC-1295 with DAC peptide vial
- Bacteriostatic water (2-5mL)
- Insulin or 1mL syringes
- Alcohol prep pads
Steps
- Clean both vial tops with alcohol and dry completely
- 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL)
- 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL)
- Inject water slowly to prevent foaming
- Let sit 5 minutes before gently rolling to mix
- Solution may appear slightly cloudy initially
- Label with date and concentration immediately
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
CJC-1295 (without DAC)
AvoidNever combine different variants; choose based on desired release pattern.
MK-677
AvoidBoth provide continuous GH elevation; combination risks excessive levels.
Tesamorelin
AvoidBoth are GHRH analogs; no additional benefit and potential receptor competition.
HGH
AvoidDefeats purpose and may suppress natural production.
Ipamorelin
MonitorContinuous GH elevation may reduce synergistic benefits of pulsatile protocols.
GHRP-6
MonitorGHRP pulse effects diminished with continuous GH elevation.
Sermorelin
MonitorCJC-1295 DAC is already more potent and long-lasting.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1
Possible water retention, improved sleep, increased appetite
- Week 2-3
Noticeable recovery improvements, some report joint discomfort
- Week 4-6
Visible body composition changes, increased vascularity
- Week 6-8
Continued improvements but watch for desensitization signs
- Post-cycle
Most gains maintained; IGF-1 returns to baseline in 2-3 weeks
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Water retention
- Joint pain
- Carpal tunnel symptoms
Stop signs — stop and seek advice
- Severe joint pain or carpal tunnel syndrome
- Excessive water retention affecting daily life
- Numbness or tingling in extremities
- Significant blood glucose dysregulation
- Signs of acromegaly (jaw growth, hand/feet enlargement)
- Persistent lethargy indicating adrenal effects
Contraindications
- Diabetes history
- Cancer history
- Predisposed sleep apnea
Monitoring
- Regular IGF-1 monitoring recommended for long-term use
- Higher incidence of side effects than pulsatile protocols
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- High purity requirement (>98%); impurities cause more side effects
- Proper DAC labeling; legitimate products clearly state 'with DAC'
Warning signs
- Higher cost than non-DAC (2-3x more due to complex manufacturing)
- Foaming during mixing is normal for DAC peptides; wait for foam to settle
Stop signs — don't use
- Extremely cheap pricing (if priced similar to non-DAC, likely mislabeled)
- Clear solution immediately (should be slightly cloudy initially)
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2025 · Endocrine Reviews
Growth Hormone-Releasing Hormone and Its Analogues in Health and Disease
Comprehensive review of GHRH and analogs including CJC-1295 across multiple therapeutic areas: wound healing, inflammation, neuroprotection, diabetes, obesity, and cardiovascular disease.
References
Primary literature and clinical-trial data informing this entry.
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhore R · Journal of Clinical Endocrinology & Metabolism · 2006
Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.
Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
Ionescu M, Frohman LA · Journal of Clinical Endocrinology & Metabolism · 2006
Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.
Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
Jette L, Bhore R, Bhatt DL, et al. · Endocrinology · 2005
Identified CJC-1295 as a long-acting GHRH analog through albumin bioconjugation (DAC technology). Binds covalently to endogenous albumin, extending half-life from minutes to days.
Activation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects
Teichman SL, et al. · Growth Hormone & IGF Research · 2009
Long-acting GHRH stimulation via CJC-1295 produces measurable changes in serum protein profiles reflecting sustained GH/IGF-1 axis activation.
Last updated . How this page was sourced is described in the methodology.